Access the full text.
Sign up today, get DeepDyve free for 14 days.
Claudia Green, G. Jost, T. Frenzel, J. Boyken, C. Schwenke, H. Pietsch (2022)The Effect of Gadolinium-Based Contrast Agents on Longitudinal Changes of Magnetic Resonance Imaging Signal Intensities and Relaxation Times in the Aging Rat Brain
Investigative Radiology, 57
J. Klostranec, Diana Vucevic, K. Bhatia, H. Kortman, T. Krings, Kieran Murphy, K. terBrugge, D. Mikulis (2021)Current Concepts in Intracranial Interstitial Fluid Transport and the Glymphatic System: Part II-Imaging Techniques and Clinical Applications.
Mihilkumar Patel, Almohannad Atyani, J. Salameh, M. McInnes, S. Chakraborty (2020)Safety of Intrathecal Administration of Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.
G. Ringstad, L. Valnes, A. Dale, A. Pripp, S. Vatnehol, K. Emblem, K. Mardal, P. Eide (2018)Brain-wide glymphatic enhancement and clearance in humans assessed with MRI.
JCI insight, 3 13
E. Kanal (2020)A Reality Check on Intrathecal Gadolinium-based Contrast Agents.
P. Eide, A. Lashkarivand, Åsmund Hagen-Kersten, Ø. Gjertsen, B. Nedregaard, Ruth Sletteberg, G. Løvland, S. Vatnehol, A. Pripp, L. Valnes, G. Ringstad (2022)Intrathecal Contrast-Enhanced Magnetic Resonance Imaging of Cerebrospinal Fluid Dynamics and Glymphatic Enhancement in Idiopathic Normal Pressure Hydrocephalus
Frontiers in Neurology, 13
Siddharth Nath, A. Koziarz, J. Badhiwala, W. Alhazzani, Roman Jaeschke, Sunjay Sharma, L. Banfield, A. Shoamanesh, Sheila Singh, F. Nassiri, W. Oczkowski, E. Belley‐Cote, R. Truant, K. Reddy, M. Meade, F. Farrokhyar, M. Bała, F. Alshamsi, M. Krag, I. Etxeandia-Ikobaltzeta, R. Kunz, O. Nishida, C. Matouk, M. Selim, A. Rhodes, G. Hawryluk, S. Almenawer (2017)Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis
The Lancet, 391
P. Eide, A. Pripp, G. Ringstad (2020)Magnetic resonance imaging biomarkers of cerebrospinal fluid tracer dynamics in idiopathic normal pressure hydrocephalus
Brain Communications, 2
M. Halvorsen, C. Edeklev, J. Fraser-Green, G. Løvland, S. Vatnehol, Ø. Gjertsen, B. Nedregaard, Ruth Sletteberg, G. Ringstad, P. Eide (2020)Off-label intrathecal use of gadobutrol: safety study and comparison of administration protocols
S. Naganawa, Rintaro Ito, H. Kawai, T. Taoka, Tadao Yoshida, M. Sone (2020)Confirmation of Age-dependence in the Leakage of Contrast Medium around the Cortical Veins into Cerebrospinal Fluid after Intravenous Administration of Gadolinium-based Contrast Agent
Magnetic Resonance in Medical Sciences, 19
Masahiro Kobayashi, Swati Levendovszky, D. Hippe, M. Hasegawa, N. Murata, K. Murata, D. Marshall, L. Gonzalez-Cuyar, K. Maravilla (2021)Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate.
H. Benveniste, Hedok Lee, B. Ozturk, Xinan Chen, S. Koundal, P. Vaska, A. Tannenbaum, N. Volkow (2020)Glymphatic Cerebrospinal Fluid and Solute Transport Quantified by MRI and PET Imaging
A. Nehra, R. McDonald, Amy Bluhm, T. Gunderson, D. Murray, P. Jannetto, D. Kallmes, L. Eckel, J. McDonald (2018)Accumulation of Gadolinium in Human Cerebrospinal Fluid after Gadobutrol-enhanced MR Imaging: A Prospective Observational Cohort Study.
Radiology, 288 2
G. Ringstad, P. Eide (2021)Safety of Intrathecal Gadolinium-based Contrast Agents and Benefit versus Risk.
Di Cao, Ningdong Kang, J. Pillai, Xinyuan Miao, Adrian Paez, Xiang Xu, Jiadi Xu, Xu Li, Q. Qin, P. Zijl, P. Barker, J. Hua (2020)Fast whole brain MR imaging of dynamic susceptibility contrast changes in the cerebrospinal fluid (cDSC MRI)
Magnetic Resonance in Medicine, 84
C. Edeklev, M. Halvorsen, G. Løvland, S. Vatnehol, Ø. Gjertsen, B. Nedregaard, Ruth Sletteberg, G. Ringstad, P.K. Eide (2019)Intrathecal Use of Gadobutrol for Glymphatic MR Imaging: Prospective Safety Study of 100 Patients
American Journal of Neuroradiology, 40
K. Deike-Hofmann, Julia Reuter, Robert Haase, D. Paech, Regula Gnirs, S. Bickelhaupt, Michael Forsting, Claus Heussel, H. Schlemmer, A. Radbruch (2019)Glymphatic Pathway of Gadolinium-Based Contrast Agents through the Brain: Overlooked and Misinterpreted
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 191
Jeffrey Iliff, Minghuan Wang, Yonghong Liao, Benjamin Plogg, Weiguo Peng, G. Gundersen, H. Benveniste, G. Vates, R. Deane, S. Goldman, E. Nagelhus, M. Nedergaard (2012)A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β
Science Translational Medicine, 4
G. Jost, T. Frenzel, Jessica Lohrke, D. Lenhard, S. Naganawa, H. Pietsch (2016)Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue
European Radiology, 27
C. Mallio, À. Rovira, P. Parizel, C. Quattrocchi (2020)Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies
Florian Berger, R. Kubik-Huch, T. Niemann, H. Schmid, Michael Poetzsch, J. Froehlich, J. Beer, M. Thali, T. Kraemer (2018)Gadolinium Distribution in Cerebrospinal Fluid after Administration of a Gadolinium-based MR Contrast Agent in Humans.
Radiology, 288 3
P. Eide, A. Pripp, G. Ringstad, L. Valnes (2021)Impaired glymphatic function in idiopathic intracranial hypertension
Brain Communications, 3
J. Akbar, P. Luetmer, K. Schwartz, C. Hunt, F. Diehn, L. Eckel (2012)The Role of MR Myelography with Intrathecal Gadolinium in Localization of Spinal CSF Leaks in Patients with Spontaneous Intracranial Hypotension
American Journal of Neuroradiology, 33
M. Hovd, E. Mariussen, H. Uggerud, A. Lashkarivand, H. Christensen, G. Ringstad, P. Eide (2022)Population pharmacokinetic modeling of CSF to blood clearance: prospective tracer study of 161 patients under work-up for CSF disorders
Fluids and Barriers of the CNS, 19
G. Ringstad, S. Vatnehol, P. Eide (2017)Glymphatic MRI in idiopathic normal pressure hydrocephalus
J. Tamargo, J. Heuzey, Phillipe Mabo (2015)Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide
European Journal of Clinical Pharmacology, 71
P. Eide, A. Pripp, Benedikte Berge, H. Hrubos-Strøm, G. Ringstad, L. Valnes (2022)Altered glymphatic enhancement of cerebrospinal fluid tracer in individuals with chronic poor sleep quality
Journal of Cerebral Blood Flow & Metabolism, 42
H. Selcuk, S. Albayram, H. Ozer, Sıla Ulus, G. Sanus, M. Kaynar, N. Kocer, C. Işlak (2010)Intrathecal Gadolinium-Enhanced MR Cisternography in the Evaluation of CSF Leakage
American Journal of Neuroradiology, 31
BACKGROUND AND PURPOSE: In our clinical practice, we increasingly use intrathecal contrast-enhanced glymphatic MR imaging to assess CSF disturbances. However, because intrathecal MR imaging contrast agents such as gadobutrol (Gadovist; 1.0 mmol/mL) are used off-label, a thorough understanding of the safety profile is required. MATERIALS AND METHODS: We performed a prospective safety study from August 2020 to June 2022 of intrathecal gadobutrol, including consecutive patients who received either 0.50, 0.25, or 0.10 mmol. Serious and nonserious adverse events were recorded systematically at 1–3 days, 4 weeks, and >6 months after the intrathecal administration. RESULTS: The study included 196 patients who received intrathecal gadobutrol, including patients assessed for idiopathic normal pressure hydrocephalus (iNPH, n = 144) or patients examined for other CSF disorders (non-iNPH cohort; n = 52). The intrathecal gadobutrol doses were either 0.50 mmol ( n = 56), 0.25 mmol ( n = 111), or 0.10 mmol ( n = 29). No serious adverse events were observed. Nonserious adverse events on days 1–3 after intrathecal gadobutrol were, to some degree, dose-dependent but mild-to-moderate, including severe headache, nausea, and/or dizziness in 6/196 (6.3%) patients, and they were more common in the non-iNPH than in the iNPH cohort. At 4 weeks, none reported severe nonserious adverse events, and 9/179 (5.0%) patients had mild-to-moderate symptoms. After >6 months, 2 patients reported mild headache. CONCLUSIONS: The present study adds to the accumulating evidence that intrathecal gadobutrol in doses up to 0.50 is safe.
American Journal of Neuroradiology – American Journal of Neuroradiology
Published: May 1, 2023
Access the full text.
Sign up today, get DeepDyve free for 14 days.